Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings

Set Alert for Sales & Earnings

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Novartis gives back Beigene PD-1; BMS revs R&D engine; Anthos changes course for Factor XI asset; the non-incretin pipeline for obesity; and a look at Q2’s top-selling drugs.

Commercial Deals

BenevolentAI Still Bullish As CEO Shields Steps Down

BenevolentAI has added Merck KGaA to its list of partners but the UK firm is looking for a new CEO after Joanna Shields decided to leave as a major restructuring continues.

Artificial Intelligence Business Strategies

Top 10 Best-Selling Drugs Of Q2 2023: COVID-19 Out, HPV In

The Merck & Co vaccine for human papillomavirus Gardasil, along with Johnson & Johnson’s Darzalex for multiple myeloma, entered the ranks of the top 10 best-selling drugs globally in the second quarter. There was no product for COVID-19 in the line-up for the first time since 2020.

Sales & Earnings Market Intelligence

Video Roundtable: APAC Team Talks Key Regional Trends And Topics

Join Scrip's APAC content team for a video overview of major trends and topics in the regional biopharma industry over the past few months.

Asia Pacific Commercial

Stock Watch: CSL Takes Knocks Punching Above Its Weight

CSL’s evolution from plasma fractioneer to biotech has reached the extent of an approved gene therapy just as gene therapy commercialization faces challenges. Meanwhile, in the post-pandemic inflationary environment, CSL’s margins in its biggest blood products division are impacted by increased donor fees and higher labor costs.

Stock Watch Commercial

Stock Watch: Lilly And Novo Provide An Earnings Season Crescendo

The commercial and clinical successes of Lilly and Novo's respective GLP-1 receptor agonists provided an explosive finale to the second-quarter earnings season but also raised questions on reimbursement.

Stock Watch Sales & Earnings

Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving

Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.

Commercial Biosimilars

Calliditas Confident Despite Cutting Tarpeyo Sales Guidance

The Swedish biotech’s immunoglobulin A nephropathy therapy Tarpeyo is still selling well but “market access friction” is slowing growth. As US regulators grant a priority review to its data package for full approval, Calliditas’s prospects look promising.

Sales & Earnings Renal

Lundbeck Pulled New Growth Levers In Q2

Rexulti launch in agitation associated with Alzheimer’s disease is under way with a branded DTC marketing campaign planned for fall.

Sales & Earnings Neurology

Aurobindo’s Pediatric AIDS Combo Generic Approved; Eugia Restructuring Back On Cards

A US FDA tentative approval for Aurobindo’s dolutegravir combination generic for children should increase access under the PEPFAR program and aid sales. On a Q1 earnings call, renewed efforts to restructure Eugia, biosimilar launch plans and fallouts of oral drug shortages and damage to Pfizer’s US injectables warehouse were discussed

Commercial Approvals

Titans Of Pharma: Pfizer’s Bourla Tops Big Pharma CEO Compensation League

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

Leadership Companies

Sun Pharma Chief: We Are Not 'All In' In Biologics

Sun stays “tentative” about a large exposure in the biosimilars segment while also outlining its approach to commercialize some diverse pipeline assets including an early stage GLP-1 receptor agonist.

Commercial Business Strategies

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Wegovy’s solid new trial results; Lilly’s sales swing back; nothing off the table for new Bayer boss; new compliance crackdown in China; and McKinsey on AI.

Commercial Sales & Earnings

Stock Watch: Pharma And Anti-Pharma

While not direct competitors in all therapeutic areas, Pfizer’s and Merck’s sales offered some stark contrasts in the second quarter.

Stock Watch Sales & Earnings

Amylyx’s Relyvrio/Albrioza Launch Chugs Along As Firm Gives EU Another Go

The company reported 3,800 ALS patients on drug, a figure that came in slightly below some analyst estimates but which suggested discontinuation rates consistent with the pivotal trial.

Sales & Earnings Neurology

Novo Bets On ‘Chequered’ CB1r Approach In Diabetic Kidney Disease With Inversago Buy

The Danish firm’s Q2 sales fell short of expectations due to poor rare disease and diabetes performance, but a potentially billion-dollar buy of Inversago stole attention as observers highlighted the historical risks of targeting the cannabinoid-1 receptor.

Sales & Earnings Companies
UsernamePublicRestriction

Register